<DOC>
	<DOCNO>NCT02045745</DOCNO>
	<brief_summary>The purpose study analyze safety feasibility implantation autologous mesenchymal stem cell ( MSCs ) expand `` vitro '' administer directly lung line suture treatment patient risk postoperative air leak lung resection .</brief_summary>
	<brief_title>Clinical Trial Phase I/II Prospective , Open Nonrandomized Treatmen Postoperative Air Leak After Lung Resection High Risk Patients Through Administration Mesenchymal Autologous Cells</brief_title>
	<detailed_description />
	<criteria>Age 18 70 year Patients subject programmed anatomic lung resection ( pneumonectomy exclude ) Patients class C D risk scale air leak Patients include study must meet inclusion criterion . Patients follow exclusion criterion may include clinical trial : Those consider investigator good position tolerate procedure Clinical criterion anesthetic contraindicate surgery Uncontrolled severe disease Pregnant woman Patients infected hepatitis B , hepatitis C , syphilis HIV + virus People take drug clinical investigation participate study clinical investigation ( authorized product ) within 30 day prior randomization The absence inform consent revocation thereof</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Postoperative air leak risk patient .</keyword>
</DOC>